Skip to main content

Palvella Therapeutics, Inc.

corporate_fare Company Profile

Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania

Exchange: NASDAQSector: Life Sciences

Palvella Therapeutics, Inc. (NASDAQ:PVLA) is a publicly traded company in the Life Sciences sector. Wiseek monitors PVLA SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Palvella Therapeutics Reports Positive Phase 2 Data for QTORIN™ Rapamycin in Cutaneous Venous Malformations
  • Palvella Therapeutics Uplists to Nasdaq Global Market
  • Palvella Therapeutics Secures $230M Equity Financing and Advances Lead Candidate Towards NDA Submission
  • Palvella Therapeutics Secures $215.8M in Equity Offering, Extends Cash Runway Amidst Increased R&D
  • Palvella Therapeutics Reports $1.20/Share Loss for Second Quarter

show_chartPrice Chart

Loading chart...

feed PVLA - Latest Insights

PVLA
May 15, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Palvella Therapeutics Reports Positive Phase 2 Data for QTORIN™ Rapamycin in Cutaneous Venous Malformations
Sentiment: Positive
View Wiseek Article
PVLA
May 13, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Palvella Therapeutics Uplists to Nasdaq Global Market
Sentiment: Positive
View Wiseek Article
PVLA
May 07, 2026, 9:09 AM EDT
Filing Type: 8-K
Importance Score:
9
Palvella Therapeutics Secures $230M Equity Financing and Advances Lead Candidate Towards NDA Submission
Sentiment: Positive
View Wiseek Article
PVLA
May 07, 2026, 8:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
Palvella Therapeutics Secures $215.8M in Equity Offering, Extends Cash Runway Amidst Increased R&D
Sentiment: Neutral
View Wiseek Article
PVLA
May 07, 2026, 7:34 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Palvella Therapeutics Reports $1.20/Share Loss for Second Quarter
Sentiment: Negative
View Wiseek Article
PVLA
May 04, 2026, 7:36 AM EDT
Source: Reuters
Importance Score:
7
Palvella Therapeutics Doses First Patients in Phase 2 Lotu Trial for Fast Track-Designated Qtorin™ Rapamycin
Sentiment: Positive
View Wiseek Article
PVLA
Apr 07, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Palvella Therapeutics Details Accelerated Pipeline, Key Regulatory Milestones, and Commercial Readiness
Sentiment: Positive
View Wiseek Article
PVLA
Mar 31, 2026, 8:30 AM EDT
Filing Type: 10-K
Importance Score:
9
Palvella Therapeutics Reports FY2025 Results, Highlights Positive Phase 3 Data & $215.8M Public Offering
Sentiment: Positive
View Wiseek Article
PVLA
Mar 31, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Palvella Therapeutics Reports Strong Clinical Progress and $230M Financing, Bolstering Pipeline and Launch Readiness
Sentiment: Positive
View Wiseek Article
PVLA
Mar 31, 2026, 7:32 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Palvella Therapeutics Reports $3.71 Per Share Loss for 2025
Sentiment: Negative
View Wiseek Article
PVLA
Mar 30, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
New Publication Validates Palvella's QTORIN™ Approach for Challenging Lymphatic Malformations
Sentiment: Positive
View Wiseek Article
PVLA
Mar 27, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Palvella's QTORIN™ Rapamycin Phase 3 SELVA Study Meets Primary & Secondary Endpoints in Rare Skin Disease
Sentiment: Positive
View Wiseek Article
PVLA
Mar 23, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Palvella Therapeutics Appoints Key Rare Disease Commercial Leader to Drive Market Access Ahead of QTORIN™ Launch
Sentiment: Positive
View Wiseek Article
PVLA
Feb 26, 2026, 5:33 PM EST
Source: Unknown
Importance Score:
8
Palvella Therapeutics Prices 1.6M-Share Offering at $125; Expects $187.3M Net, TD/Cantor/Stifel
Sentiment: Negative
View Wiseek Article
PVLA
Feb 26, 2026, 5:31 PM EST
Filing Type: 8-K
Importance Score:
8
Palvella Therapeutics Prices $216M Offering at 22% Discount to Fund Pipeline Development
Sentiment: Negative
View Wiseek Article
PVLA
Feb 24, 2026, 4:27 PM EST
Filing Type: 424B5
Importance Score:
8
Palvella Therapeutics Launches $150M Public Offering with Pre-Funded Warrants Following Positive Phase 3 Results
Sentiment: Neutral
View Wiseek Article
PVLA
Feb 24, 2026, 4:23 PM EST
Filing Type: 8-K
Importance Score:
7
Palvella Therapeutics Reports $55.9M Preliminary Cash Balance as of Year-End 2025, Preceding $150M Offering
Sentiment: Neutral
View Wiseek Article
PVLA
Feb 24, 2026, 6:30 AM EST
Filing Type: 8-K
Importance Score:
9
Palvella Therapeutics Announces Positive Phase 3 Results for QTORIN™ Rapamycin in Microcystic LMs, Plans H2 2026 NDA
Sentiment: Positive
View Wiseek Article
PVLA
Jan 29, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Palvella Therapeutics Unveils Robust Pipeline & 2026 Catalysts, Including March Phase 3 Data
Sentiment: Positive
View Wiseek Article
PVLA
Jan 12, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Palvella Therapeutics Details Positive Phase 2 Data, Upcoming Phase 3 Readout, and Pipeline Growth
Sentiment: Positive
View Wiseek Article